Sympathoexcitation associated with renin-angiotensin system in metabolic syndrome

Takuya Kishi, Yoshitaka Hirooka

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Renin-angiotensin system (RAS) is activated in metabolic syndrome (MetS), and RAS inhibitors are preferred for the treatments of hypertension with MetS. Although RAS activation is important for the therapeutic target, underlying sympathetic nervous system (SNS) activation is critically involved and should not be neglected in the pathogenesis of hypertension with MetS. In fact, previous studies have suggested that SNS activation has the interaction with RAS activation and/or insulin resistance. As a novel aspect connecting the importance of SNS and RAS activation, we and other investigators have recently demonstrated that angiotensin II type 1 receptor (AT1R) blockers (ARBs) improve SNS activation in patients with MetS. In the animal studies, SNS activation is regulated by the AT1R-induced oxidative stress in the brain. We have also demonstrated that orally administered ARBs cause sympathoinhibition independent of the depressor effects in dietary-induced hypertensive rats. Interestingly, these benefits on SNS activation of ARBs in clinical and animal studies are not class effects of ARBs. In conclusion, SNS activation associated with RAS activation in the brain should be the target of the treatment, and ARBs could have the potential benefit on SNS activation in patients with MetS.

Original languageEnglish
Article number406897
JournalInternational Journal of Hypertension
Volume2013
DOIs
Publication statusPublished - Mar 15 2013

Fingerprint

Sympathetic Nervous System
Renin-Angiotensin System
Hypertension
Angiotensin II Type 1 Receptor Blockers
Angiotensin Type 1 Receptor
Brain
Insulin Resistance
Oxidative Stress
Therapeutics
Research Personnel

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Sympathoexcitation associated with renin-angiotensin system in metabolic syndrome. / Kishi, Takuya; Hirooka, Yoshitaka.

In: International Journal of Hypertension, Vol. 2013, 406897, 15.03.2013.

Research output: Contribution to journalReview article

@article{9544a980c250444cbdc0cc6b200ee9f0,
title = "Sympathoexcitation associated with renin-angiotensin system in metabolic syndrome",
abstract = "Renin-angiotensin system (RAS) is activated in metabolic syndrome (MetS), and RAS inhibitors are preferred for the treatments of hypertension with MetS. Although RAS activation is important for the therapeutic target, underlying sympathetic nervous system (SNS) activation is critically involved and should not be neglected in the pathogenesis of hypertension with MetS. In fact, previous studies have suggested that SNS activation has the interaction with RAS activation and/or insulin resistance. As a novel aspect connecting the importance of SNS and RAS activation, we and other investigators have recently demonstrated that angiotensin II type 1 receptor (AT1R) blockers (ARBs) improve SNS activation in patients with MetS. In the animal studies, SNS activation is regulated by the AT1R-induced oxidative stress in the brain. We have also demonstrated that orally administered ARBs cause sympathoinhibition independent of the depressor effects in dietary-induced hypertensive rats. Interestingly, these benefits on SNS activation of ARBs in clinical and animal studies are not class effects of ARBs. In conclusion, SNS activation associated with RAS activation in the brain should be the target of the treatment, and ARBs could have the potential benefit on SNS activation in patients with MetS.",
author = "Takuya Kishi and Yoshitaka Hirooka",
year = "2013",
month = "3",
day = "15",
doi = "10.1155/2013/406897",
language = "English",
volume = "2013",
journal = "International Journal of Hypertension",
issn = "2090-0384",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Sympathoexcitation associated with renin-angiotensin system in metabolic syndrome

AU - Kishi, Takuya

AU - Hirooka, Yoshitaka

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Renin-angiotensin system (RAS) is activated in metabolic syndrome (MetS), and RAS inhibitors are preferred for the treatments of hypertension with MetS. Although RAS activation is important for the therapeutic target, underlying sympathetic nervous system (SNS) activation is critically involved and should not be neglected in the pathogenesis of hypertension with MetS. In fact, previous studies have suggested that SNS activation has the interaction with RAS activation and/or insulin resistance. As a novel aspect connecting the importance of SNS and RAS activation, we and other investigators have recently demonstrated that angiotensin II type 1 receptor (AT1R) blockers (ARBs) improve SNS activation in patients with MetS. In the animal studies, SNS activation is regulated by the AT1R-induced oxidative stress in the brain. We have also demonstrated that orally administered ARBs cause sympathoinhibition independent of the depressor effects in dietary-induced hypertensive rats. Interestingly, these benefits on SNS activation of ARBs in clinical and animal studies are not class effects of ARBs. In conclusion, SNS activation associated with RAS activation in the brain should be the target of the treatment, and ARBs could have the potential benefit on SNS activation in patients with MetS.

AB - Renin-angiotensin system (RAS) is activated in metabolic syndrome (MetS), and RAS inhibitors are preferred for the treatments of hypertension with MetS. Although RAS activation is important for the therapeutic target, underlying sympathetic nervous system (SNS) activation is critically involved and should not be neglected in the pathogenesis of hypertension with MetS. In fact, previous studies have suggested that SNS activation has the interaction with RAS activation and/or insulin resistance. As a novel aspect connecting the importance of SNS and RAS activation, we and other investigators have recently demonstrated that angiotensin II type 1 receptor (AT1R) blockers (ARBs) improve SNS activation in patients with MetS. In the animal studies, SNS activation is regulated by the AT1R-induced oxidative stress in the brain. We have also demonstrated that orally administered ARBs cause sympathoinhibition independent of the depressor effects in dietary-induced hypertensive rats. Interestingly, these benefits on SNS activation of ARBs in clinical and animal studies are not class effects of ARBs. In conclusion, SNS activation associated with RAS activation in the brain should be the target of the treatment, and ARBs could have the potential benefit on SNS activation in patients with MetS.

UR - http://www.scopus.com/inward/record.url?scp=84874893269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874893269&partnerID=8YFLogxK

U2 - 10.1155/2013/406897

DO - 10.1155/2013/406897

M3 - Review article

C2 - 23476747

AN - SCOPUS:84874893269

VL - 2013

JO - International Journal of Hypertension

JF - International Journal of Hypertension

SN - 2090-0384

M1 - 406897

ER -